Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme a reductase inhibitors on non-high-density lipoprotein cholesterol levels
Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme a reductase inhibitors on non-high-density lipoprotein cholesterol levels
复制标题
DOI：
10.1016/s0002-9149(01)01638-1
复制
发表时间：
2001-08-01
影响因子：
2.8
通讯作者：
Shear, C
中科院分区：
文献类型：
--
作者：
Ballantyne, CM;Andrews, TC;Shear, C
载脂蛋白B已被证明是一个更好的预测冠心病比低密度脂蛋白（LDL）胆固醇，和非高密度脂蛋白（非HDL）胆固醇也可能是一个更好的参数，冠心病的风险评估和治疗的目标。阿托伐他汀比较胆固醇疗效和安全性研究（ACCESS）的数据用于评估降脂治疗前后血脂和载脂蛋白B水平之间的相关性，并检查5羟甲基戊二酰辅酶A还原酶抑制剂对血脂和载脂蛋白B的影响。这项为期54周的研究将3，916名高胆固醇血症患者随机分配至阿托伐他汀、氟伐他汀、洛伐他汀、普伐他汀或辛伐他汀组，以推荐的起始剂量开始，并在第6、12和18周根据需要进行滴定，以达到国家胆固醇教育计划LDL目标。与低密度脂蛋白胆固醇相比，非高密度脂蛋白胆固醇与基线载脂蛋白B水平的相关性更好（r = 0.914，p
Apolipoprotein B has been shown to be a better predictor of coronary heart disease than low-density lipoprotein (LDL) cholesterol, and non-high-density lipoprotein (non-HDL) cholesterol may also be a better parameter for coronary heart disease risk assessment and as a target for therapy. Data from the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) were used to assess the correlation between lipid and apolipoprotein B levels before and after lipid-lowering therapy and to examine the effects of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on lipids and apolipoprotein B. The 54-week study randomized 3,916 hypercholesterolemic patients to atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin, initiated at recommended starting doses with titrations as needed at weeks 6, 12, and 18 to achieve National Cholesterol Education Program LDL targets. Compared with LDL cholesterol, non-HDL cholesterol correlated better with apolipoprotein B levels at baseline (r = 0.914, p